Insider · CIK 0001910662

LaBrosse Nicole

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001910662

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-23	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+6,688 sh	—	—	42,102
2026-02-23	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−3,608 sh	$70.64	−$255K	38,494
2026-02-23	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−6,688 sh	—	—	36,357
2026-02-20	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+5,332 sh	—	—	38,290
2026-02-20	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−2,876 sh	$70.98	−$204K	35,414
2026-02-20	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−5,332 sh	—	—	15,995
2026-02-16	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+5,093 sh	—	—	27,172
2026-02-16	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−2,747 sh	$79.44	−$218K	24,425
2026-02-16	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+5,329 sh	—	—	29,754
2026-02-16	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−2,874 sh	$79.44	−$228K	26,880
2026-02-16	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+13.4K sh	—	—	40,231
2026-02-16	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−7,273 sh	$79.44	−$578K	32,958
2026-02-16	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−5,093 sh	—	—	0
2026-02-16	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−5,329 sh	—	—	5,329
2026-02-16	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−13.4K sh	—	—	0
2026-02-09	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+5,167 sh	—	—	13,351
2026-02-09	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+7,448 sh	—	—	43,045
2026-02-09	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+29.5K sh	—	—	29,502
2025-09-22	HALOHALOZYME THERAPEUTICS, INC.S Sale	SVP, CHIEF FINANCIAL OFFICER	SSale	−1,913 sh	$77.83	−$149K	22,393
2025-09-22	HALOHALOZYME THERAPEUTICS, INC.S Sale	SVP, CHIEF FINANCIAL OFFICER	SSale	−314 sh	$78.67	−$24.7K	22,079
2025-09-10	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+11.3K sh	$12.07	+$136K	43,171
2025-09-10	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+1,135 sh	$12.49	+$14.2K	44,306
2025-09-10	HALOHALOZYME THERAPEUTICS, INC.S Sale	SVP, CHIEF FINANCIAL OFFICER	SSale	−6,760 sh	$75.29	−$509K	37,546
2025-09-10	HALOHALOZYME THERAPEUTICS, INC.S Sale	SVP, CHIEF FINANCIAL OFFICER	SSale	−13.2K sh	$75.93	−$1.01M	24,306
2025-09-10	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−11.3K sh	—	—	0
2025-09-10	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−1,135 sh	—	—	812
2025-02-23	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+6,688 sh	—	—	35,501
2025-02-23	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−3,601 sh	$57.75	−$208K	31,900
2025-02-23	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−6,688 sh	—	—	20,063
2025-02-20	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+22.6K sh	—	—	22,603
2025-02-20	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+21.3K sh	—	—	21,327
2025-02-16	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+17.4K sh	—	—	33,402
2025-02-16	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−9,400 sh	$58.29	−$548K	24,002
2025-02-16	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+5,093 sh	—	—	29,095
2025-02-16	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−2,742 sh	$58.29	−$160K	26,353
2025-02-16	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+5,329 sh	—	—	31,682
2025-02-16	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−2,869 sh	$58.29	−$167K	28,813
2025-02-16	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−17.4K sh	—	—	0
2025-02-16	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−5,093 sh	—	—	5,093
2025-02-16	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−5,329 sh	—	—	10,658
2025-02-15	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+1,254 sh	—	—	16,734
2025-02-15	HALOHALOZYME THERAPEUTICS, INC.F Tax Payment	SVP, CHIEF FINANCIAL OFFICER	FTax Payment	−741 sh	$58.29	−$43.2K	15,993
2025-02-15	HALOHALOZYME THERAPEUTICS, INC. · Restricted Stock UnitsM Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	−1,254 sh	—	—	0
2025-02-12	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+6,050 sh	—	—	17,409
2025-02-12	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+5,221 sh	—	—	8,184
2025-02-12	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+6,935 sh	—	—	6,935
2025-02-12	HALOHALOZYME THERAPEUTICS, INC. · Performance Stock UnitsA Award	SVP, CHIEF FINANCIAL OFFICER	AAward	+28.7K sh	—	—	28,662
2024-07-22	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+4,008 sh	$22.50	+$90.2K	19,488
2024-07-22	HALOHALOZYME THERAPEUTICS, INC.S Sale	SVP, CHIEF FINANCIAL OFFICER	SSale	−4,008 sh	$53.85	−$216K	15,480
2024-07-22	HALOHALOZYME THERAPEUTICS, INC.M Exercise/Conversion	SVP, CHIEF FINANCIAL OFFICER	MExercise/Conversion	+992 sh	$22.50	+$22.3K	16,472

Recent filings

Accepted (ET)
Feb 244
LaBrosse Nicole0001159036-26-000029
SEC(opens sec.gov)
Feb 174
LaBrosse Nicole0001159036-26-000026
SEC(opens sec.gov)
Feb 114
LaBrosse Nicole0001159036-26-000015
SEC(opens sec.gov)
Sep 234
LaBrosse Nicole0001910662-25-000003
SEC(opens sec.gov)

Companies

HALOZYME THERAPEUTICS, INC.SVP, CHIEF FINANCIAL OFFICERHALO

Address

C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL

SAN DIEGO, CA, 92130